ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients
After initially issuing a complete response and denial of the individual drugs in 2013 to Gilead, the FDA approved the drugs last week.
Last week the White House announced the President’s Council of Advisors on Science and Technology (PCAST) release of a report to the President, Combating Antibiotic Resistance. The report was released simultaneously with a National Strategy on Combating Antibiotic Resistant Bacteria as well as with a Presidential Executive Order, emphasizing to the Nation the importance of addressing this growing challenge.
2014 NFID Fall Clinical Vaccinology Course scheduled for November 7-9, 2014 at the Houston Marriott at the Texas Medical Center in Houston, TX.
Early registration closes on September 29, 2014! Register before then to save $100.
Earn up to 19.75 hours of continuing education credit (CME, CNE, CPE).
Please click here for details and registration.
CLSI 2015 Antimicrobial Susceptibility Testing Update
February 4, 2015 or February 5 1015
1:00 - 2:30 PM ET 3:00 - 4:30 PM ET
Registration Deadline: February 2, 2015
Early Bird Pricing Available!
Register online by 1/7/15 to qualify.
Each January, CLSI updates standards for antimicrobial susceptibility testing (AST). It is important for clinical laboratories to incorporate the new recommendations into routine practice to optimize detection and reporting of antimicrobial resistance. In January 2015, the annual update of the M100 tables (CLSI document M100-S25) will publish. In addition, there will be updates to the standards that describe performance of disk diffusion and MIC tests in versions M02-A12 and M07-A10, respectively. Some highlights for 2015 include introduction of the carbaNP test for carbapenemases and expanded recommendations for quality control testing. These changes and several other new recommendations found in M100-S25, M02-A12 and M07-A10 will be
discussed. In addition to the webinar, an optional postprogram self-assessment
will be provided that will allow individuals to assess their knowledge regarding the
most important AST and reporting issues for 2015. Laboratories can use this
feature to augment competency assessment requirements for their staff.
Janet A. Hindler, MCLS MT(ASCP), Sr. Specialist, Clinical Microbiology, UCLA Health System, Los Angeles, CA
This intermediate-level program is appropriate for laboratory professionals working in clinical and academic settings.
CONTINUING EDUCATION is available
Registration fee is per site for one connection to the live program with unlimited
attendance (and CEUs) for everyone AND unlimited access (and CEUs) to the archive program for 6 months
Early Bird Special $110: Register online by January 7, 2015
Regular fee: $125 when you register by registration form or online after January 7, 2015
Site facilitator must register online at www.aphl.org/courses/pages/588-950-15.aspx. Having difficulty with the online registration process? Please email email@example.com or call 240.485.2727 from 8:00 AM to 4:30 PM ET
Triumeq (ABACAVIR SULFATE;DOLUTEGRAVIR;LAMIVUDINE)
was approved by the FDA on August 22nd, marking the second once daily integrase combination approved but without the drug interactions and intolerances associated with cobicistat in the QUAD pill. Information from the SINGLE trial is available from the CROI 2014 meeting and a review of the agent in N Engl J Med. 2013;369:1807-1818.
After initial rejection in 2008, Oritavancin is approved today with the gateway indication for acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), various Streptococcus species and Enterococcus faecalis. Oritavancin now joins dalbavancin, approved May 2014 and tedizolid approved June 2014 for similar indications, all with unique profiles. The data exceeds this space so for more information, you can always review the CDER brief but objective review for dalbavancin and tedizolid. Review papers from the 2000s for oritavancin basics. Three new drugs courtesy of the GAIN act. Looking forward to the new beta lactamase inhibitor and cephalosporin for new gram negative pathogen options.
BACK TO THE PATIENT:
SEPTEMBER 6, 2014
7:00 AM - 9:00 AM
MEETING ROOM 206
WALTER E. WASHINGTON CONVENTION CENTER
801 MT VERNON PLACE NW
ANTHONY D. HARRIS, MD, MPH
Professor of Medicine
University of Maryland Medical Center, Baltimore, MD
This session will educate the clinician on how to identify patient centered outcomes to measure the performance of an ASP, including the feasibility of capturing such measures and consideration of the changing healthcare landscape in the era of healthcare reform.
CRAIG A. MARTIN, PHARMD, BCPS
Clinical Associate Professor
Department of Pharmacy Practice and Services
University of Kentucky College of Pharmacy, Lexington, KY
This session will inform the clinician on various types of quasiexperimental studies, including the advantages and disadvantages of each type and consideration of variability in resource availability.
For more information and to register, view the summary.
Live CE Webinar
The Role of Antimicrobial
Testing and Reporting
in Antibiotic StewardshipWednesday, August 27, 2014 - 2:00-3:00pm CT
Information derived from antibiotic susceptibility testing (AST) can be a powerful tool in determining appropriate selection, dosing, and duration of antibiotics. The standards for how this testing is performed change on an annual basis and can influence the results that the clinician uses to make treatment determinations.
This session will provide an overview of the current Clinical and Laboratory Standards Institute (CLSI) breakpoints and discuss new concepts such as the addition of the category of “susceptible – dose dependent” or S-DD. The most effective way to utilize AST results and apply them at the bedside will also be discussed. The format for the activity will include examples of laboratory reports and clinician responses to these reports as discussed by the speakers in an interactive format.
August 27, 2014 - 2:00–3:00pm Central Time
(fee waived for SIDP, ACCP ID PRN, and ACCP CRIT PRN Members
with special code/ check your email for the code)
For additional information and to register: Click Here
James S. Lewis II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator
& Adjunct Associate Professor
Oregon Health and Science University
Janet A. Hindler, MCLS, MT(ASCP)
Sr. Specialist, Clinical Microbiology
UCLA Health System
· List the CLSI standards for antimicrobial susceptibility testing introduced in 2014.
· Discuss strategies for reporting antimicrobial test results to best influence appropriate therapy.
· Describe ways in which the microbiology lab can contribute to antibiotic stewardship and confront contemporary antimicrobial reporting and antimicrobial prescribing challenges.
Can’t make the live webinar?
This webinar is scheduled to be available On-Demand at http://www.proce.com/AntimicrobialTesting
beginning September 24, 2014.
This CE activity is co-sponsored by ProCE, Inc., CLSI, and SIDP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-14-162-L01-P has been assigned to this knowledge-based live CE activity (initial release date 8-27-14). This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Successful completion of an online post-test and evaluation at www.ProCE.com is required to receive CE credit. No partial credit will be given.
Funding:This activity is self-funded by SIDP, CLSI, and members of ACCP ID PRN and ACCP CRIT PRN.
The Society of Infectious Diseases Pharmacists
2014 Call for Grant Applications to Fund Two
Infectious Diseases Pharmacotherapy Young Investigator
The Society of Infectious Diseases Pharmacists (SIDP) is a dynamic association of health professionals dedicated to promoting the appropriate use of antimicrobials. SIDP is committed to excellence in infectious diseases education, pharmacotherapy, and research. One of the missions of SIDP is to promote research endeavors.
SIDP is soliciting ID pharmacotherapy research proposals from SIDP members who qualify as young investigators [£5 years from completion of their terminal training (e.g., residency, fellowship, graduate degree)]. The primary purpose of the research award is to provide funding for research projects that will contribute to the further development of the principal investigator’s research career and improve their competitiveness for future extramural funding. Favorable consideration will be given to research proposals which focus on current pharmacotherapy issues surrounding the prevention and management of infectious diseases.
Proposals should be converted to a single PDF file adhering to the format described above. The PDF file of the proposal is then electronically submitted to both Stephanie Bulak (firstname.lastname@example.org) and the Chair of the Research Committee, David E. Nix (email@example.com).
Proposals must be submitted online no later than 5PM E.S.T. on Friday, August 8, 2014.
For further details, click here.
Society of Infectious Diseases Pharmacists • 403 W. Saint Charles, Suite B, Lombard, IL 60148
(331) 248-7888 • firstname.lastname@example.org
Proudly Managed by Affinity Strategies